The Conflict of Interests With a Pelvic Pharmaceuticals

A pelvis pharmaceuticals recently received approval for a treatment for an eye disease called geographic atrophy. But in July, there were reports of a pretty severe form of eye inflammation that have hopped up. About seven cases of this have appeared since the drug was launched commercially. The company's stock price has plummeted and it's compounded by the fact that the cause of this ROV side effect is really not known.